Substituted fused pyrazole compounds and their use as LRRK2 inhibitors
申请人:GlaxoSmithKline Intellectual Property Development Limited
公开号:US10975081B2
公开(公告)日:2021-04-13
Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.
[EN] HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QUE RÉCEPTEUR DE DÉCLENCHEMENT EXPRIMÉ SUR DES AGONISTES DE CELLULES MYÉLOÏDES 2 ET PROCÉDÉS D'UTILISATION
申请人:VIGIL NEUROSCIENCE INC
公开号:WO2022236272A3
公开(公告)日:2022-12-22
HETEROCYCLIC COMPOUNDS, PARTICULARLY PYRIMIDINYLINDAZOLE COMPOUNDS FOR TREATING PARKINSON'S DISEASE
申请人:GlaxoSmithKline Intellectual Property Development
Limited
公开号:EP3325449B1
公开(公告)日:2021-01-13
COMPOUNDS
申请人:GlaxoSmithKline Intellectual Property Development
Limited